ReviewNeurology2019
A brief history of "Alzheimer disease": Multiple meanings separated by a common name.
Review in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.Alzheimer's research & therapy · 2022Pooled it
- Clinical-biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.Brain : a journal of neurology · 2026Article
- The many meanings of Alzheimer's disease and why they matter for policy, research, and care.GeroScience · 2026Article
- Multidomain therapy for Alzheimer's disease: a scoping review of cognitive decline trials.Molecular neurodegeneration · 2025Article
- Alzheimer Disease Blood Biomarker Concentrations Across Race and Ethnicity Groups in Middle-Aged Adults.JAMA network open · 2025Article
- The Role of Oxidative Stress in the Relationship Between Periodontitis and Alzheimer's Disease: A Review of the Literature.Journal of personalized medicine · 2025Review
- Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort.Alzheimer's research & therapy · 2025Article
- Advances in Molecular Imaging for the Early Detection and Management of Alzheimer's Disease.Cureus · 2025Article
- [Preface for Special Issue on Alzheimer's Disease: New Diagnostic Criteria, Treatment, and the Role of Neuroimaging].Journal of the Korean Society of Radiology · 2025Article
- Allostatic Interoceptive Overload Across Psychiatric and Neurological Conditions.Biological psychiatry · 2025Review
- The role of quantitative EEG biomarkers in Alzheimer's disease and mild cognitive impairment: applications and insights.Frontiers in aging neuroscience · 2025Review
- New criteria to predict LATE-NC in the clinical setting: Probable/Possible LATE and LANS.Journal of neuropathology and experimental neurology · 2025Review
- Considering Biomarkers of Neurodegeneration in Alzheimer's Disease: The Potential of Circulating Cell-Free DNA in Precision Neurology.Journal of personalized medicine · 2024Review
- Ex vivo propagation of synaptically-evoked cortical depolarizations in a mouse model of Alzheimer's disease at 20 Hz, 40 Hz, or 83 Hz.Scientific reports · 2024Article
- Beyond the usual suspects: multi-factorial computational models in the search for neurodegenerative disease mechanisms.Translational psychiatry · 2024Review
- Amyloid PET disclosure in subjective cognitive decline: Patient experiences over time.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Central inhibition of stearoyl-CoA desaturase has minimal effects on the peripheral metabolic symptoms of the 3xTg Alzheimer's disease mouse model.Scientific reports · 2024Article
- Biomarker-based staging of Alzheimer disease: rationale and clinical applications.Nature reviews. Neurology · 2024Review
- Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History.Journal of clinical medicine · 2024Review
- A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.Brain communications · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The field of Alzheimer disease (AD) has a nosologic problem: The diagnostic label "Alzheimer disease" has several distinctive meanings. The term probable AD was introduced in 1984 to designate a clinically diagnosed acquired and progressive amnestic dementia for which there was no evidence for another etiology. Probable AD represented a clinicopathologic entity that assumed a specific and sensitive linkage between amnestic dementia and the neuropathology of β-amyloid-containing neuritic plaques and tau-containing neurofibrillary tangles. The clinicopathologic model represented by probable AD was adapted in abbreviated form for population-based studies and general clinical practice, although the uncertainty connoted by "probable" was often overlooked. Representing the growing public awareness of later life cognitive impairment, a vernacular meaning of AD arose out of the clinicopathologic model in which AD represented all dementia not due to another clinically apparent cause. In contrast, by the 1990s, neuropathologists settled on a definition of AD based entirely on a sufficient burden of neuritic plaques and neurofibrillary tangles at postmortem examination, regardless of antemortem clinical status. In the last decade, the availability of fluid and imaging biomarkers that measure β-amyloid and tau abnormalities has enabled antemortem pathobiological diagnoses, highlighting the divide between the clinicopathologic model, the vernacular usage, and the pathobiological models. Each definition has value. However, the meanings of AD as defined by each of these models are not interchangeable. The pathobiological one is the only one that is unambiguous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.